News 13/16

SOBI presents positive data of Doptelet in patients suffering from cITP and thrombocytopenia

ipharmaservices

Dec 9, 2019

Roche’s Xofluza (baloxavir marboxil) was approved by the US FDA for influenza

ipharmaservices

Oct 20, 2019

Pfizer-BMS and Fitbit collaborate to develop devices to detect atrial fibrillation

ipharmaservices

Oct 19, 2019

GSK and Lyell Immunopharma join in developing cell therapies against solid tumours

ipharmaservices

Oct 9, 2019

Janssen’s niraparib received breakthrough designation for metastatic castration-prostate cancer

ipharmaservices

Oct 4, 2019

Novartis collaborated with Microsoft to transform medicine

ipharmaservices

Oct 3, 2019

SOBI acquired Dova Pharmaceuticals

ipharmaservices

Sep 30, 2019

CHMP Positive Opinions: September

ipharmaservices

Sep 23, 2019

Cosentyx trial data indicate that the drug is ready to get approval for the fourth indication

ipharmaservices

Sep 18, 2019

Lundbeck acquired Alder BioPharmaceuticals – a company specialized in migraine treatment

ipharmaservices

Sep 17, 2019

AstraZeneca’s Farxiga received fast track designation from US FDA

ipharmaservices

Sep 17, 2019

US FDA approved Ofev for treatment of interstitial lung disease associated with systemic sclerosis

ipharmaservices

Sep 9, 2019

Novartis capmatinib (INC280) received breakthrough designation by FDA

ipharmaservices

Sep 9, 2019

FDA approved Kyowa Kirin’s Nourianz for adults with Parkinson’s disease

ipharmaservices

Aug 29, 2019

BMS Emplicti is approved by European Commission for patients suffering from relapsed and refractory

ipharmaservices

Aug 29, 2019

Lilly’s Taltz received US FDA approval for the treatment of active ankylosing spondylitis

ipharmaservices

Aug 26, 2019

Amgen to acquire Celgene’s Otezla for $13.2 billion

ipharmaservices

Aug 26, 2019

AstraZeneca’s & FibroGen’s Roxadustat was approved in China for patients with CKD patients

ipharmaservices

Aug 23, 2019

FDA approved Nabriva Therapeutics’ Xenleta (lefamulin) for community-acquired bacterial pneumonia

ipharmaservices

Aug 21, 2019

Pfizer invests half-billion dollars on gene-therapy facility in Sanford

ipharmaservices

Aug 21, 2019

iPharmaCenter

ipharmacenter Consulting services

SOBI presents positive data of Doptelet in patients suffering from cITP and thrombocytopenia

Roche’s Xofluza (baloxavir marboxil) was approved by the US FDA for influenza

Pfizer-BMS and Fitbit collaborate to develop devices to detect atrial fibrillation

GSK and Lyell Immunopharma join in developing cell therapies against solid tumours

Janssen’s niraparib received breakthrough designation for metastatic castration-prostate cancer

Novartis collaborated with Microsoft to transform medicine

SOBI acquired Dova Pharmaceuticals

CHMP Positive Opinions: September

Cosentyx trial data indicate that the drug is ready to get approval for the fourth indication

Lundbeck acquired Alder BioPharmaceuticals – a company specialized in migraine treatment

AstraZeneca’s Farxiga received fast track designation from US FDA

US FDA approved Ofev for treatment of interstitial lung disease associated with systemic sclerosis

Novartis capmatinib (INC280) received breakthrough designation by FDA

FDA approved Kyowa Kirin’s Nourianz for adults with Parkinson’s disease

BMS Emplicti is approved by European Commission for patients suffering from relapsed and refractory

Lilly’s Taltz received US FDA approval for the treatment of active ankylosing spondylitis

Amgen to acquire Celgene’s Otezla for $13.2 billion

AstraZeneca’s & FibroGen’s Roxadustat was approved in China for patients with CKD patients

FDA approved Nabriva Therapeutics’ Xenleta (lefamulin) for community-acquired bacterial pneumonia

Pfizer invests half-billion dollars on gene-therapy facility in Sanford